

# Aris Persidis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10684962/publications.pdf>

Version: 2024-02-01

36  
papers

1,145  
citations

567281

15  
h-index

377865

34  
g-index

38  
all docs

38  
docs citations

38  
times ranked

1726  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer multidrug resistance. <i>Nature Biotechnology</i> , 1999, 17, 94-95.	17.5	284
2	Literature mining, ontologies and information visualization for drug repurposing. <i>Briefings in Bioinformatics</i> , 2011, 12, 357-368.	6.5	200
3	Drug repurposing and adverse event prediction using high-throughput literature analysis. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2011, 3, 323-334.	6.6	100
4	Proteomics. <i>Nature Biotechnology</i> , 1998, 16, 393-394.	17.5	72
5	High-throughput screening. <i>Nature Biotechnology</i> , 1998, 16, 488-489.	17.5	66
6	Signal transduction as a drug-discovery platform. <i>Nature Biotechnology</i> , 1998, 16, 1082-1083.	17.5	43
7	Bioentrepreneurship around the world. <i>Nature Biotechnology</i> , 1998, 16, 3-4.	17.5	43
8	The business of pharmacogenomics. <i>Nature Biotechnology</i> , 1998, 16, 209-210.	17.5	36
9	Biochips. <i>Nature Biotechnology</i> , 1998, 16, 981-983.	17.5	24
10	Pharmacogenomics and diagnostics. <i>Nature Biotechnology</i> , 1998, 16, 791-792.	17.5	23
11	From depression to neurodegeneration and heart failure: re-examining the potential of MAO inhibitors. <i>Expert Review of Clinical Pharmacology</i> , 2012, 5, 413-425.	3.1	23
12	Ribozyme therapeutics. <i>Nature Biotechnology</i> , 1997, 15, 921-922.	17.5	21
13	Literature analysis for systematic drug repurposing: a case study from Biovista. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2011, 8, 103-108.	0.5	19
14	The carbohydrate-based drug industry. <i>Nature Biotechnology</i> , 1997, 15, 479-480.	17.5	17
15	Bioinformatics. <i>Nature Biotechnology</i> , 1999, 17, 828-830.	17.5	17
16	Autoimmune disease drug discovery. <i>Nature Biotechnology</i> , 1999, 17, 1038-1038.	17.5	15
17	Systems literature analysis. <i>Pharmacogenomics</i> , 2004, 5, 943-947.	1.3	15
18	Biochips: An Evolving Clinical Technology. <i>Hospital Practice (1995)</i> , 1999, 34, 67-85.	1.0	14

#	ARTICLE	IF	CITATIONS
19	Biotechnologies to watch. Nature Biotechnology, 1997, 15, 1409-1411.	17.5	11
20	Biotechnology consortia versus multifirm alliances: Paradigm shift at work?. Nature Biotechnology, 1996, 14, 1657-1660.	17.5	9
21	Data mining in biotechnology. Nature Biotechnology, 2000, 18, 237-238.	17.5	7
22	Critical issues in gene therapy commercialization. Nature Biotechnology, 1997, 15, 689-690.	17.5	6
23	Artificial intelligence for drug design. Nature Biotechnology, 1997, 15, 1035-1036.	17.5	6
24	Combinatorial chemistry. Nature Biotechnology, 1998, 16, 691-693.	17.5	6
25	Cardiovascular disease drug discovery. Nature Biotechnology, 1999, 17, 930-931.	17.5	6
26	Catalytic antibodies. Nature Biotechnology, 1997, 15, 1313-1315.	17.5	5
27	Biotechnology in 1998 and beyond. Nature Biotechnology, 1998, 16, 1378-1379.	17.5	5
28	Strategies of biotechnology firms towards new, platform technologies. International Journal of Biotechnology, 2001, 3, 23.	1.2	5
29	Pharmacogenomics and diagnostics. Nature Biotechnology, 1998, 16, 20-21.	17.5	4
30	Arthritis drug discovery. Nature Biotechnology, 1999, 17, 726-728.	17.5	4
31	Mental disorder drug discovery. Nature Biotechnology, 1999, 17, 307-309.	17.5	4
32	Lead validation platforms. Nature Biotechnology, 1998, 16, 100-101.	17.5	3
33	Functional antigenics. Nature Biotechnology, 1998, 16, 305-307.	17.5	2
34	Biotechnology valuation. Nature Biotechnology, 1997, 15, 813-814.	17.5	1
35	Consolidations in biotechnology. Nature Biotechnology, 1999, 17, BE3-BE4.	17.5	1
36	Biotechnology 2000. Nature Biotechnology, 1999, 17, 1239-1239.	17.5	1